
Lauren Allen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9905022/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
4	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
5	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	6.3	519
6	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	6.3	430
7	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
8	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nature Protocols, 2021, 16, 3114-3140.	5.5	195
9	Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. Nature Communications, 2021, 12, 81.	5.8	141
10	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nature Communications, 2021, 12, 1260.	5.8	115
11	Anti-Group B Streptococcus antibody in infants born to mothers with human immunodeficiency virus (HIV) infection. Vaccine, 2015, 33, 621-627.	1.7	34
12	Development of a large scale human complement source for use in bacterial immunoassays. Journal of Immunological Methods, 2013, 391, 39-49.	0.6	20
13	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	4.7	20
14	Placental transfer of anti-group B Streptococcus immunoglobulin G antibody subclasses from HIV-infected and uninfected women to their uninfected infants. Aids, 2016, 30, 471-475.	1.0	17
15	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. Communications Biology, 2021, 4, 915.	2.0	15
16	Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: An investigational vaccine component against Neisseria meningitidis. Vaccine, 2012, 30, 1330-1342.	1.7	10
17	Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma. Methods in Molecular Biology, 2022, 2414, 341-362.	0.4	8
18	Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England. Vaccine Journal, 2015, 22, 503-509.	3.2	7

#	Article	IF	CITATIONS
19	A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage. Science Translational Medicine, 2021, 13, .	5.8	7
20	Solid sorbitan esters nanoparticles are efficient and low-cost vehicles for subunit vaccines: Proof of concept with Neisseria meningitidis protein Mip. Journal of Drug Delivery Science and Technology, 2017, 42, 299-306.	1.4	1